Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Repare Therapeutics Inc (NQ: RPTX ) 3.180 -0.060 (-1.85%) Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Repare Therapeutics Inc < Previous 1 2 3 Next > Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI June 26, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial June 10, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer June 04, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 03, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 May 29, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results May 07, 2024 From Repare Therapeutics Inc. Via Business Wire Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition April 30, 2024 From Debiopharm Via Business Wire Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition April 30, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors April 26, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 21, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings March 15, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences February 29, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results February 28, 2024 From Repare Therapeutics Inc. Via Business Wire REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Repare Stockholders and Encourages Investors to Contact the Firm February 20, 2024 From Bragar Eagel & Squire Via GlobeNewswire Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX) February 16, 2024 From Kirby McInerney LLP Via Business Wire Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 February 15, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Regain Global Rights to Camonsertib February 12, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment January 25, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones January 08, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer January 04, 2024 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans December 29, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor November 15, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results November 09, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast November 07, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate in Two Upcoming Investor Conferences November 06, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib October 13, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics October 03, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics September 19, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference September 06, 2023 From Repare Therapeutics Inc. Via Business Wire Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10 August 10, 2023 Via Investor Brand Network < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.